Skip to Main Content

For further information, see CMDT Part 24-19: Neuromyelitis Optica

Key Features

  • Previously known as Devic disease and once regarded as a variant of multiple sclerosis

  • Associated with a specific antibody marker (NMO-IgG) targeting the water channel aquaporin-4 in 80% of cases, and with antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) in a third of NMO-IgG seronegative patients

Clinical Findings

  • Optic neuritis and acute myelitis with MRI changes that extend over at least three segments of the spinal cord

  • Isolated myelitis or optic neuritis may also occur


  • MRI of the brain typically does not show widespread white matter involvement, but such changes do not exclude the diagnosis


  • Eculizumab

    • FDA approved

    • A complement inhibitor that reduced the annualized relapse rate from 35% to 2% compared to placebo

    • Requires prior immunization against meningococcus

  • Inebilizumab

    • FDA-approved

    • A humanized anti-CD19 antibody that depletes B cells

    • Reduced relapse rate compared to placebo in a randomized trial

  • Alteratives include

    • Rituximab

      • Two 1-g intravenous infusions spaced by 2 weeks, or four weekly infusions of 375 mg/m2

      • Re-dosing may occur every 6 months or when CD19/20-positive or CD27-positive lymphocytes become detectable

    • Mycophenolate mofetil, 500–1500 mg orally twice daily, titrated until the absolute lymphocyte count falls below 1500/mcL

    • Azathioprine, 2.5–3 mg/kg orally

  • Corticosteroids used for acute relapses

  • Plasma exchange given when severe relapses do not respond to corticosteroids

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.